Klatzkow Sarah, Davis Garrett, Shmalberg Justin, Gallastegui Aitor, Miscioscia Erin, Tarricone Jason, Elam Lindsay, Johnson Matthew D, Leonard Katelyn M, Wakshlag Joseph J
Department of Small Animal Surgery, Red Bank Veterinary Hospital, Tinton Falls, NJ, United States.
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, United States.
Front Vet Sci. 2023 Jan 4;9:1036056. doi: 10.3389/fvets.2022.1036056. eCollection 2022.
To determine the impact of a cannabidiol (CBD) and cannabidiolic acid (CBDA) rich hemp product on acute post-operative pain in dogs following a tibial plateau leveling osteotomy (TPLO), and to evaluate for changes in early bone healing, serum chemistry profiles, and complete blood counts.
In this randomized, placebo controlled, blinded clinical trial, 44 client-owned dogs were assigned to receive either a CBD/CBDA product dosed at 2-2.5 mg/kg PO every 12 h or a placebo for 4 weeks following a TPLO. Variables evaluated before (week 0), and at 2 and 4 weeks post-operatively included standardized veterinary assessments for pain score, weight-bearing, and lameness, the Canine Brief Pain Inventory (pain interference score-PIS, pain severity score-PSS), and serum biochemistry. Complete blood counts were performed at weeks 0 and 4. Additionally, orthogonal radiographs evaluating the degree of healing were taken at week 4. A mixed model analysis, analyzing changes of variables of interest from enrollment baseline to all other time points was utilized, with a -value ≤ 0.05 considered significant.
Of the 44 enrolled patients, 3 were lost to follow up and excluded from analysis. No significant differences were noted between placebo ( = 19) and CBD/CBDA ( = 22) groups at any point in pain score, degree of lameness, degree of weight-bearing, PIS, PSS, or radiographic healing of the osteotomy. A significant finding of elevation of ALP above normal reference range in the treatment group was identified ( = 0.02) and eosinophil count was affected by treatment ( = 0.01), increasing from baseline in placebo and decreasing in treatment groups. Finally, a significant difference ( = 0.03) was noted at 2 weeks post-operatively where 4 patients in the placebo group and no treatment patients received trazodone to facilitate activity restrictions.
Use of a CBD/CBDA rich hemp product dosed at 2-2.5 mg/kg PO every 12 h did not have a significant impact on pain or delay early bone healing. A statistically significant increase in ALP, decrease in eosinophils, and reduced use of trazodone was identified in the treatment group.
确定一种富含大麻二酚（CBD）和大麻二酚酸（CBDA）的大麻产品对犬胫骨平台水平截骨术（TPLO）后急性术后疼痛的影响，并评估早期骨愈合、血清化学指标和全血细胞计数的变化。
在这项随机、安慰剂对照、双盲临床试验中，44只客户拥有的犬在TPLO术后被分配接受每12小时口服2 - 2.5 mg/kg的CBD/CBDA产品或安慰剂，为期4周。在术前（第0周）以及术后2周和4周评估的变量包括疼痛评分、负重和跛行的标准化兽医评估、犬简短疼痛量表（疼痛干扰评分 - PIS、疼痛严重程度评分 - PSS）以及血清生化指标。在第0周和第4周进行全血细胞计数。此外，在第4周拍摄评估愈合程度的正交X线片。采用混合模型分析，分析从入组基线到所有其他时间点感兴趣变量的变化，P值≤0.05被认为具有统计学意义。
44例入组患者中，3例失访并被排除在分析之外。在疼痛评分、跛行程度、负重程度、PIS、PSS或截骨术的X线愈合方面，安慰剂组（n = 19）和CBD/CBDA组（n = 22）在任何时间点均未观察到显著差异。在治疗组中发现碱性磷酸酶（ALP）升高至高于正常参考范围有统计学意义（P = 0.02），嗜酸性粒细胞计数受治疗影响（P = 0.01），在安慰剂组中从基线升高，在治疗组中降低。最后，在术后2周观察到显著差异（P = 0.03），安慰剂组有4例患者且无治疗组患者接受曲唑酮以促进活动限制。
每12小时口服2 - 2.5 mg/kg的富含CBD/CBDA的大麻产品对疼痛或早期骨愈合延迟没有显著影响。在治疗组中发现碱性磷酸酶有统计学意义的升高、嗜酸性粒细胞减少以及曲唑酮使用减少。
